High-tech problem for Joe Biden’s COVID vaccine patent waiver

Published May 8, 2021 12:00am ET



The difficulty of learning the technology behind mRNA vaccines poses a major obstacle to President Joe Biden’s proposal aiding poor countries by defying the pharmaceutical industry and waiving patent protections for COVID-19 vaccines.

The rationale for the patent waiver would be to allow developing countries to reproduce currently existing COVID-19 vaccines without having to worry about getting sued by the pharmaceutical companies that hold the patents.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.